Pharma Q3 Earnings Preview: Domestic Revival, Exports Traction Hint At Normalcy Convergence, Says ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Our healthcare universe (12 coverage companies) is expected to post decent YoY growth of approximately 10% to Rs 44685 crore led by a significant revival in domestic sales and growth in U.S. formulations led by new launches and specialty ramp-up.
Domestic growth is expected to be led by partial recovery in acute segment, reasonable traction in the chronic segment and Covid-19 related product sales supported by sequentially higher medical representative footfalls.
U.S. formulations are expected to grow due to ramp-up in specialty products and new launches supported by currency tailwinds.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.